291 related articles for article (PubMed ID: 15164602)
21. Gallbladder bile tumor marker quantification for detection of pancreato-biliary malignancies.
Brockmann J; Emparan C; Hernandez CA; Sulkowski U; Dietl KH; Menzel J; Wolters H; Glodny B; Senninger N
Anticancer Res; 2000; 20(6D):4941-7. PubMed ID: 11326643
[TBL] [Abstract][Full Text] [Related]
22. Are serum and biliary carcinoembryonic antigen and carbohydrate antigen19-9 determinations reliable for differentiation between benign and malignant biliary disease?
Akdoğan M; Parlak E; Kayhan B; Balk M; Saydam G; Sahin B
Turk J Gastroenterol; 2003 Sep; 14(3):181-4. PubMed ID: 14655062
[TBL] [Abstract][Full Text] [Related]
23. Serum CA 242 in pancreatic cancer. Comparison with CA 19-9 and CEA.
Pezzilli R; Billi P; Plate L; Laudadio MA; Sprovieri G
Ital J Gastroenterol; 1995; 27(6):296-9. PubMed ID: 8562994
[TBL] [Abstract][Full Text] [Related]
24. Preoperative differential diagnosis of benign and malignant pancreatic lesions--the value of pancreatic secretory trypsin inhibitor, procarboxypeptidase B, CA19-9 and CEA.
Cerwenka H; Aigner R; Quehenberger F; Werkgartner G; Bacher H; Hauser H; Mischinger HJ
Hepatogastroenterology; 1997; 44(16):1117-21. PubMed ID: 9261609
[TBL] [Abstract][Full Text] [Related]
25. [The significance of urine di-acetyl spermine level as a cancer marker for colorectal cancer].
Takahashi K; Hiramatsu K; Kawakita M; Mori T; Yamaguchi T; Matsumoto H; Miyamoto H; Tamamori Y
Rinsho Byori; 2004 Apr; 52(4):332-5. PubMed ID: 15164601
[TBL] [Abstract][Full Text] [Related]
26. Elevated tumour marker CA19-9: clinical interpretation and influence of obstructive jaundice.
Mann DV; Edwards R; Ho S; Lau WY; Glazer G
Eur J Surg Oncol; 2000 Aug; 26(5):474-9. PubMed ID: 11016469
[TBL] [Abstract][Full Text] [Related]
27. CA19-9 serum levels in obstructive jaundice: clinical value in benign and malignant conditions.
Marrelli D; Caruso S; Pedrazzani C; Neri A; Fernandes E; Marini M; Pinto E; Roviello F
Am J Surg; 2009 Sep; 198(3):333-9. PubMed ID: 19375064
[TBL] [Abstract][Full Text] [Related]
28. CEA, CA 19-9 and CA 72-4 improve the diagnostic accuracy in gastrointestinal cancers.
Carpelan-Holmström M; Louhimo J; Stenman UH; Alfthan H; Haglund C
Anticancer Res; 2002; 22(4):2311-6. PubMed ID: 12174919
[TBL] [Abstract][Full Text] [Related]
29. Comparison of tumor marker CA 242 with CA 19-9 and carcinoembryonic antigen (CEA) in pancreatic cancer.
Ozkan H; Kaya M; Cengiz A
Hepatogastroenterology; 2003; 50(53):1669-74. PubMed ID: 14571813
[TBL] [Abstract][Full Text] [Related]
30. Clinical significance of cathepsin E in pancreatic juice in the diagnosis of pancreatic ductal adenocarcinoma.
Uno K; Azuma T; Nakajima M; Yasuda K; Hayakumo T; Mukai H; Sakai T; Kawai K
J Gastroenterol Hepatol; 2000 Nov; 15(11):1333-8. PubMed ID: 11129230
[TBL] [Abstract][Full Text] [Related]
31. Clinical value of serum TAG-72 as a tumor marker for pancreatic carcinoma. Comparison with CA 19-9.
Pasquali C; Sperti C; D'Andrea AA; Costantino V; Filipponi C; Pedrazzoli S
Int J Pancreatol; 1994 Jun; 15(3):171-7. PubMed ID: 7930777
[TBL] [Abstract][Full Text] [Related]
32. Multivariate analysis of six serum tumor markers (CEA, CA 50, CA 242, TPA, TPS, TATI) and conventional laboratory tests in the diagnosis of hepatopancreatobiliary malignancy.
Pasanen PA; Eskelinen M; Partanen K; Pikkarainen P; Penttilä I; Alhava E
Anticancer Res; 1995; 15(6B):2731-7. PubMed ID: 8669855
[TBL] [Abstract][Full Text] [Related]
33. Preoperative serum carcinoembryonic antigen and carbohydrate antigen 19-9 levels for the evaluation of curability and resectability in patients with pancreatic adenocarcinoma.
Fujioka S; Misawa T; Okamoto T; Gocho T; Futagawa Y; Ishida Y; Yanaga K
J Hepatobiliary Pancreat Surg; 2007; 14(6):539-44. PubMed ID: 18040617
[TBL] [Abstract][Full Text] [Related]
34. The role of different tumor markers in the early diagnosis and prognosis of pancreatic carcinoma and chronic pancreatitis.
Hámori J; Arkosy P; Lenkey A; Sápy P
Acta Chir Hung; 1997; 36(1-4):125-7. PubMed ID: 9408313
[TBL] [Abstract][Full Text] [Related]
35. Combined detection of serum tumor markers for differential diagnosis of solid lesions located at the pancreatic head.
Liao Q; Zhao YP; Yang YC; Li LJ; Long X; Han SM
Hepatobiliary Pancreat Dis Int; 2007 Dec; 6(6):641-5. PubMed ID: 18086633
[TBL] [Abstract][Full Text] [Related]
36. A comparison of tumour M2-PK with carcinoembryonic antigen and CA19-9 in patients undergoing liver resection for colorectal metastases.
Kumar Y; Pinedo IR; Tapuria N; Zabron A; Davidson BR
Eur J Gastroenterol Hepatol; 2008 Oct; 20(10):1006-11. PubMed ID: 18787469
[TBL] [Abstract][Full Text] [Related]
37. The diagnostic importance of CEA and CA 19-9 for the early diagnosis of pancreatic carcinoma.
Nazli O; Bozdag AD; Tansug T; Kir R; Kaymak E
Hepatogastroenterology; 2000; 47(36):1750-2. PubMed ID: 11149048
[TBL] [Abstract][Full Text] [Related]
38. [Role of carcinoembryonic antigen, carbohydrate antigen 19-9 and cytology of bile in diagnosis of biliary and pancreatic cancer].
Matsuda M; Shimizu Y; Chikamatsu E; Takayanagi K; Ishigure H; Murakami S; Odani K
Nihon Geka Gakkai Zasshi; 1991 Jun; 92(6):716-21. PubMed ID: 1886576
[TBL] [Abstract][Full Text] [Related]
39. Carcinoembryonic antigen messenger RNA expression using nested reverse transcription-PCR in the peripheral blood during follow-up period of patients who underwent curative surgery for biliary-pancreatic cancer: longitudinal analyses.
Mataki Y; Takao S; Maemura K; Mori S; Shinchi H; Natsugoe S; Aikou T
Clin Cancer Res; 2004 Jun; 10(11):3807-14. PubMed ID: 15173089
[TBL] [Abstract][Full Text] [Related]
40. [Detection and clinical study of serum tumor markers in patients with colorectal cancer].
Zhao XW; Jiang B; Han CZ; Jing JX
Zhonghua Zhong Liu Za Zhi; 2005 May; 27(5):286-8. PubMed ID: 15996321
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
